Abstract 1203P
Background
Acute myeloid leukemia (AML) is the most common leukemia in adults and current methods rely on cytogenic and molecular profiling for AML classification. Recent advances have demonstrated that next generation sequencing (NGS) may improve prognostic prediction and risk stratification of AML patients. A tumour-only high coverage whole genome sequencing (WGS) method was developed to assess the analytical performance (limit of detection (LoD)), sensitivity, specificity and reproducibility) in identifying somatic small variants, structural variants (SV) and copy number alterations (CNA) specific to AML.
Methods
Seracare® myeloid panel, NOMO1, Kasumi1, HCC1187 and 53 AML clinical specimens were used to assess analytical performance. Extracted genomic DNA (∼350ng) from contrived specimens, cell lines, mononuclear cells from whole blood or bone marrow aspirate were manually processed with Illumina DNA PCR Free Prep and sequenced at 4 plex on S4 flowcells using NovaSeq™ 6000. The sequence data was analysed by DRAGEN™ Somatic v4.2 with a custom virtual 156 AML specific gene panel variant classification algorithm.
Results
The samples were sequenced at an average of ∼220X which yielded high analytical sensitivity, accuracy and reproducibility of the specimens evaluated in this study. Although the target sequence was ∼220X, samples were in silico down sampled to 140X to establish the following performance specifications. LoD was established for small variant (SNVs and indels) and SV to be 5% and 7.3%, respectively. CNA were detected with copy number fold change of 1.09 and 0.87 for duplication and deletion events, respectively. Further, loss of heterozygosity was detected with purity of 17%. Overall, we observed accuracy >95% across clinical samples with analytical sensitivities >95%, >99% and >95% for small variants, SV and CNA, respectively and analytical specificity of >99.9%.
Conclusions
We have developed a tumour only WGS method for genomic profiling of AML patients with a turn around time of 5 days. The analytical performance of this tumour only WGS approach indicates high accuracy in identifying variants indicative for AML. In addition, the high sequence depth provides improved analytical sensitivity compared to other genome sequencing or cytogenetic methods.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Illumina.
Funding
Illumina.
Disclosure
G. Malagoli Tagliazucchi, W. Gong, M. Ghildiyal, M. Chavez, K. Nobuta, E. Sayyari, S. Truong, T. Vang, G. Kim, Q. Bui, S. Kim, J. Bernd, E. De Feo, S. Comer: Financial Interests, Institutional, Full or part-time Employment: Illumina. M. Yaylaoglu: Financial Interests, Personal and Institutional, Full or part-time Employment: Illumina. D. Spencer: Financial Interests, Institutional, Financially compensated role: Washington University in St. Louis.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10